In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?
In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?
Created by
Presenter
Anne C. Goldberg, MD, FNLA, FACP, FAHA
Professor of Medicine Division of Endocrinology, Metabolism & Lipid Research Washington University in St. Louis St. Louis, MO